Draft monograph: Tesamorelin — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-TESAMORELIN-/001. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
2. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-TESAMORELIN-/007. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
3. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-TESAMORELIN-/011. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
4. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-TESAMORELIN-/008. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
5. Trials are described as terminated where they completed as planned — arising from DRAFT-TESAMORELIN-/013. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
6. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-TESAMORELIN-/003. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
7. The search date is not on the face of the document — arising from DRAFT-TESAMORELIN-/009. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
8. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-TESAMORELIN-/006. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
9. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-TESAMORELIN-/002. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
10. The preclinical section is extensive and the clinical section is not — arising from DRAFT-TESAMORELIN-/015. The preclinical section is reduced in length, placed after the clinical assessment rather than before it, and opens with a standing statement that an effect observed in an animal model is not a clinical outcome and does not support a certainty rating.
11. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-TESAMORELIN-/004. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.